AI Article Synopsis

  • - Cyclophilin B (CypB) is linked to important biological processes like immune response and cell growth, and recent research indicates its role in cancer progression and drug resistance, especially in non-small cell lung cancer (NSCLC).
  • - A study analyzed PPIB (the gene encoding CypB) expression in 431 NSCLC samples and found that high PPIB levels in adenocarcinomas were associated with worse outcomes, including lymph node metastasis, advanced disease stages, and higher mortality rates.
  • - The combination of high PPIB and Ki-67 (a marker for cell proliferation) was identified as a significant predictor of poor survival in adenocarcinomas, highlighting the potential role of

Article Abstract

Cyclophilin B (CypB), encoded by peptidylprolyl isomerase B (), is involved in cellular transcriptional regulation, immune responses, chemotaxis, and proliferation. Recent studies have shown that PPIB/CypB is associated with tumor progression and chemoresistance in various cancers. However, the clinicopathologic significance and mechanism of action of PPIB/CypB in non-small cell lung cancer (NSCLC) remain unclear. In this study, we used RNA in situ hybridization to examine PPIB expression in 431 NSCLC tissue microarrays consisting of 295 adenocarcinomas (ADCs) and 136 squamous cell carcinomas (SCCs). Additionally, Ki-67 expression was evaluated using immunohistochemistry. The role of PPIB/CypB was assessed in five human NSCLC cell lines. There was a significant correlation between PPIB/CypB expression and Ki-67 expression in ADC (Spearman correlation =0.374, <0.001) and a weak correlation in SCC (=0.229, =0.007). In ADCs, high PPIB expression (PPIB) was associated with lymph node metastasis (=0.023), advanced disease stage (=0.014), disease recurrence (=0.013), and patient mortality (=0.015). Meanwhile, high Ki-67 expression (Ki-67) was correlated with male sex, smoking history, high pT stage, lymph node metastasis, advanced stage, disease recurrence, and patient mortality in ADC (all <0.001). However, there was no association between either marker or clinicopathological factors, except for old age and PPIB (=0.038) in SCC. Survival analyses revealed that the combined expression of PPIB/Ki-67 was an independent prognosis factor for poor disease-free survival (HR 1.424, 95% CI 1.177-1.723, <0.001) and overall survival (HR 1.266, 95% CI 1.036-1.548, =0.021) in ADC, but not in SCC. Furthermore, PPIB/CypB promoted the proliferation, colony formation, and migration of NSCLC cells. We also observed the oncogenic properties of PPIB/CypB expression in human bronchial epithelial cells. In conclusion, PPIB/CypB contributes to tumor growth in NSCLC, and elevated PPIB/Ki-67 levels are linked to unfavorable survival, especially in ADC.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10915315PMC
http://dx.doi.org/10.62347/TYNU2341DOI Listing

Publication Analysis

Top Keywords

tumor progression
8
ki-67 expression
8
ppib/cyclophilin expression
4
expression associates
4
associates tumor
4
progression unfavorable
4
unfavorable survival
4
survival patients
4
patients pulmonary
4
pulmonary adenocarcinoma
4

Similar Publications

Overexpressed AXL kinase is involved in various human malignancies, which incurs tumor progression, poor prognosis, and drug resistance. Suppression of the aberrant AXL axis with genetic tools or small-molecule inhibitors has achieved valid antitumor efficacies in both preclinical studies and clinical antitumor campaigns. Herein we will report the design, synthesis, and structure-activity relationship (SAR) exploration of a series of anilinopyrimidine type II AXL inhibitors.

View Article and Find Full Text PDF

Introduction: Tumorous growths in the sellar region pose significant clinical challenges due to their proximity to critical visual structures such as the optic chiasm and optic nerves. Given their proximity to the optic system, these tumors are often diagnosed due to a progressive decrease in visual acuity. Thus, surgical intervention is crucial to prevent irreversible damage, as timely decompression can halt the progression of edema and subsequent optic atrophy.

View Article and Find Full Text PDF

Overcoming luminal breast cancer (BrCa) progression remains a critical challenge for improved overall patient survival. RUNX2 has emerged as a protein related to aggressiveness in triple-negative BrCa, however its role in luminal tumors remains elusive. We have previously shown that active FGFR2 (FGFR2-CA) contributes to increased tumor growth and that RUNX2 expression was high in hormone-independent mouse mammary carcinomas.

View Article and Find Full Text PDF

Oncolytic measles virus-induced cell killing in radio-resistant and drug-resistant nasopharyngeal carcinoma.

Malays J Pathol

December 2024

Universiti Tunku Abdul Rahman, M. Kandiah Faculty of Medicine and Health Sciences, Department of Pre-clinical Sciences, Bandar Sungai Long, 43000, Kajang, Selangor, Malaysia.

Introduction: The current first-line therapy for nasopharyngeal carcinoma (NPC) is often associated with long-term complications. Oncolytic measles virus (MV) therapy offers a promising alternative to cancer therapy. This study aims to investigate the efficacy of MV in killing NPC cells in vitro, both with or without resistance to radiation and drug therapy.

View Article and Find Full Text PDF

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.

Malays J Pathol

December 2024

National Institutes of Health, Institute for Medical Research, Cancer Research Centre, Haematology Unit, 40170 Shah Alam, Selangor, Malaysia.

Introduction: The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs imatinib mesylate (IM) binding capacity, thus contributing to IM resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML) patients. Our study aims to determine the frequency of BCR::ABL1 KD mutations in CML patients with IM resistance.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!